Brian Rini, Cezary Szczylik, Nizar M. Tannir, Piotr Koralewski, Piotr Tomczak, Andrzej Deptala, Luc Y. Dirix, Mayer Fishman, Rodryg Ramlau, Alain Ravaud, Wojciech Rogowski, Karolyn Kracht, Yu-Nien Sun, Michael B. Bass, Markus Puhlmann and Bernard Escudier AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney Cancer 118
Article first published online: 12 JUN 2012 | DOI: 10.1002/cncr.27632
This randomized, controlled study assessed the tolerability and antitumor activity of AMG 386 plus sorafenib in patients with clear cell metastatic renal cell carcinoma. The combination was tolerable but did not significantly improve progression-free survival compared with placebo plus sorafenib.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.